Scientific instruments manufacturer Bruker Corporation BRKR recently launched its MALDI Tissuetyper solution, based on the new high-speed instrument platform – rapifleX MALDI-TOF Mass Spectrometry system.
According to the company, hindrances faced earlier in mass spectrometry imaging (MSI) can be dealt with utilizing rapifleX system’s speed, throughput, ease-of-use, robustness and spatial resolution. Bruker believes that the new MALDI Tissuetyper solution, when combined with the rapifleX system, will redefine the key performance measures for MALDI imaging and make way for entirely new projects and measurement strategies. Moreover, using Bruker’s break-through, proprietary smartbeam 3D laser, the Tissuetyper solution will work up to 20 times faster than traditional MALDI-TOF systems.
We are impressed to note that, while the market for anatomical pathology or biomarker research is growing widely, tissue-typing of protein signature distributions has become one of the most potent techniques available in this field. Current research results show impressive potential for clinical pathology applications in tumor staging, supporting therapy decisions or disease prognosis.
We believe the newly launched rapifleX-based MALDI Tissuetyper will successfully capture market share in this niche with its exclusive statistical analysis software and bioinformatics tools for data mining, as well as visualization of two-dimensional and even three-dimensional imaging datasets from multiple tissue sections.
Over the recent past, Bruker has made significant progress in its MALDI product line with a handful of product launches. Apart from MALDI Tissuetyper, the latest additions include the MALDI Sepsityper solution and MALDI Biotypersmart system, both of which received the CE Mark in Europe during the first quarter. The MALDI Sepsityper is used for rapid microbial identification from positive blood cultures, whereas the new MALDI Biotypersmart system provides high-speed analysis when integrated with the new MALDI Sepsitype. In another recent press release, the company introduced a major version 3.0 expansion of the proven Mycobacteria Library for research use only on the MALDI Biotyper microbial mass spectrometry system.
Zacks Rank
At the moment, Bruker retains a Zacks Rank #3 (Hold). Some better-ranked companies worth reckoning are Bio-Rad Laboratories, Inc. BIO, Hospira Inc. HSP and Vascular Solutions Inc. VASC. All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment